Skip to main content
. 2021 Dec 5;48:102205. doi: 10.1016/j.redox.2021.102205

Fig. 4.

Fig. 4

Heme-induced TLR4 signaling activates AKT to inhibit complex V activity.

(A) Representative western blot and quantification of pAKT/total AKT in platelets treated with heme (2.5 μM) in the presence or absence of BX795 (TBK1 inh; 2 μM), N-[1-[2-(4-Morpholinyl) ethyl]-1H-benzimidazol-2-yl]-3-nitrobenzamide (IRAK1/4 inh; 100 nM) or (5Z)-7-Oxozeaenol (TAK1 inh; 5 nM). (B) Platelet mitochondrial complex V activity (C) the ratio of phosphorylated to total complex V beta subunit, (D) MitoSOX fluorescence and (E) thrombospondin-1 release in heme treated platelets pre-treated with or without ARQ092 (10 μM). Data are represented as Mean ± SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01, ns – not significant. n = 4.